This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giaccone, G. Articles by Soria, J.-C. Search for Related Content PubMed PubMed Citation Articles by Giaccone, G. Articles by Soria, J.-C. Related Collections Commentary

Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study

Authors' Affiliations: Departments of ¹ Medical Oncology and ² Pulmonary Diseases, Vrije Universiteit Medical Center, Amsterdam, the Netherlands; ³ Institut Gustave Roussy, Paris, France; ⁴ Christie Hospital, Manchester NHS Trust, Manchester, United Kingdom; ⁵ Dana-Farber Cancer Center, Boston, Massachusetts; and ⁶ Hoffmann-La Roche Ltd., Basel, Switzerland

Requests for reprints: Giuseppe Giaccone, Department of Medical Oncology, Vrije Universiteit Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands. Phone: 31-20-444-4321; Fax: 31-20-444-4079; E-mail: g.giaccone{at}vumc.nl.

Purpose: Erlotinib has proven activity in pretreated patients with advanced non–small cell lung cancer (NSCLC). We evaluated erlotinib in the frontline treatment of advanced NSCLC and assessed biological predictors of outcome.

Experimental Design: In this phase II study, chemotherapy-naive patients with stage IIIB/IV NSCLC received oral erlotinib (150 mg/d) until disease progression or unacceptable toxicity occurred. Tumor response was assessed every 6 weeks, and samples were analyzed for potential molecular markers of treatment response and survival. The primary end point was the proportion of patients without disease progression after 6 weeks of treatment.

Results: Fifty-three patients were eligible. The overall rate of nonprogression at 6 weeks was 52.8% (28 of 53 patients). Tumor response rate was 22.7%, with 1 complete response, 11 partial responses, and 16 cases of stable disease. Responses were seen across most patient clinical characteristics. The median duration of tumor response was 333 days; median overall survival was 391 days; and median time to disease progression was 84 days. Erlotinib was well tolerated, the main treatment-related adverse events being mild-to-moderate rash and diarrhea. Histologic material for biological studies was available in 29 cases. Four of five responders and one patient with stable disease had a classic epidermal growth factor receptor tyrosine kinase mutation. Two progressing patients exhibited epidermal growth factor receptor point mutations (one with T790M mutation), and K-ras mutations were detected in 10 nonresponders.

Conclusions: Erlotinib shows significant antitumor activity in the first-line treatment of advanced NSCLC and may be a viable alternative to chemotherapy. Patient selection cannot easily be based on clinical or biological variables.

Commentary

Can a Single Pill Replace Doublet Chemotherapy in First-Line Therapy of Advanced Non–Small Cell Lung Cancer?

Paul A. Bunn, Jr.
Clin. Cancer Res. 2006 12: 5919-5920. [Full Text] [PDF]

This article has been cited by other articles:

				P. A. Zucali, M. G. Ruiz, E. Giovannetti, A. Destro, M. Varella-Garcia, K. Floor, G. L. Ceresoli, J. A. Rodriguez, I. Garassino, P. Comoglio, et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors Ann. Onc., September 1, 2008; 19(9): 1605 - 1612. [Abstract] [Full Text] [PDF]

				M.-J. Ahn, B.-B. Park, J. S. Ahn, S. W. Kim, H.-T. Kim, J. S. Lee, J. H. Kang, J. Y. Cho, H. S. Song, S. H. Park, et al. Are There Any Ethnic Differences in Molecular Predictors of Erlotinib Efficacy in Advanced Non-Small Cell Lung Cancer? Clin. Cancer Res., June 15, 2008; 14(12): 3860 - 3866. [Abstract] [Full Text] [PDF]

				P. Wheatley-Price, K. Ding, L. Seymour, G. M. Clark, and F. A. Shepherd Erlotinib for Advanced Non-Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21 J. Clin. Oncol., May 10, 2008; 26(14): 2350 - 2357. [Abstract] [Full Text] [PDF]

				G. D'Addario, D. Rauch, R. Stupp, M. Pless, R. Stahel, N. Mach, L. Jost, L. Widmer, C. Tapia, M. Bihl, et al. Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03 Ann. Onc., April 1, 2008; 19(4): 739 - 745. [Abstract] [Full Text] [PDF]

				B. E. Johnson, D. Jackman, and P. A. Janne Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non Small Cell Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4628s - 4631s. [Abstract] [Full Text] [PDF]

				B. Wacker, T. Nagrani, J. Weinberg, K. Witt, G. Clark, and P. J. Cagnoni Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies Clin. Cancer Res., July 1, 2007; 13(13): 3913 - 3921. [Abstract] [Full Text] [PDF]

				C. Gridelli, M. A. Bareschino, C. Schettino, A. Rossi, P. Maione, and F. Ciardiello Erlotinib in Non-Small Cell Lung Cancer Treatment: Current Status and Future Development Oncologist, July 1, 2007; 12(7): 840 - 849. [Abstract] [Full Text] [PDF]